Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant mFOLFIRINOX vs mFolfox6 in Rectal Cancer
NCT06812728Phase 2Recruiting
- Sponsor
- Menoufia University
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan in rectal cancer (2 arms), sponsored by Menoufia University. Primary endpoint: Complete Clinical Response Rate at 6 months. Started Jan 2025; status: recruiting.
02
Drugs
irinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06812728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812728.